Previous month Previous day Next day Next month
By Year By Month By Week Today Search Jump to month

What's new in immunotherapies 2022

Download as iCal file
Tuesday, 7. June 2022 09:00 - 18:00

Immunotherapy is a hot-topic field of research that has generated significant scientific interest and fuelled industrial innovation.

It has been demonstrated that small, drug-like molecules can be highly effective modulators of immune response pathways and that their molecular properties can be fine-tuned to enable excellent cell permeability and bioavailability. This makes them ideal for use in the treatment of chronic conditions such as autoimmune and inflammation-related diseases. Excitingly, this approach also offers the possibility to treat cancer by harnessing the body’s own immune system to fight tumours.

This meeting will offer a broad introduction to those new to the topic and showcase recent innovations by academic and industrial scientists in this exciting and rapidly expanding field.

Call for posters

An abstract of maximum one A4 page or 300 words indicating title and authors should be sent to This email address is being protected from spambots. You need JavaScript enabled to view it. by Monday 31 January 2022 with the subject line “What's New in Immunotherapies - poster abstract submission". Please use the template attached here.


The event is targeted at research students, researchers, academic and industrial scientists engaged in all aspects of research into small molecule immunotherapy, and those interested in broadening their knowledge in this growing field.

This event is being held back to back with "Targeting protein degradation 3 – from discovery to the clinic".


Confirmed speakers: 

In vitro assays for immunotherapy drug discovery programs; overview and emerging areas
Dr Rhoanne McPherson, Concept Life Sciences                 

Optimisation of Mer/Axl kinase inhibitors for immuno-oncology
Dr William McCoull, AstraZeneca

The discovery of BD2 selective BET inhibitors
Dr Emmanuel Demont, GlaxoSmithKline

First-in-class inhibitors of ERAP1 alter the immunopeptidome of cancer, driving a differentiated T cell response leading to tumour growth inhibition
Dr Andrew Leishman, Grey Wolf therapeutics

Discovery and Development of novel Small Molecule Inhibitors of IL-17
Dr Anne Foley, UCB

Professor Edward Tate, Imperial College

Enabling natural killer cell immunotherapy of cancer with small molecules
Professor Matthew J. Fuchter, Imperial College



Location : London - UK
Contact : SCI